Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced better-than-expected revenue in Q1 CY2026, with sales up 5.2% year on year to $...
Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.
The financial markets received a much-needed breath of fresh air this week as the Bureau of Labor Statistics released the Producer Price Index (PPI) report for March 2026. Final demand prices rose by 0.5%, a figure that, while indicating growth, came in substantially lower than the 1.1% consensus
The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]
As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (NYSE: BDX). Known colloquially as BD, the firm has spent the last two years shedding its skin, moving from a broad-based healthcare conglomerate to a high-growth, high-margin "pure-play" medical [...]
As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a "steady Eddie" of the MedTech world that provided everything from basic syringes to complex diagnostic laboratory equipment. However, the recent completion of the Biosciences [...]
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Over the last six months, BD’s shares have sunk to $160.20, producing a disappointing 14.6% loss while the S&P 500 was flat. This was partly due to its softe...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...
